Publications by authors named "Joanna Przewrocka"
Article Synopsis
- The study investigates the role of the APOBEC3B (A3B) enzyme in lung cancer, specifically in non-small-cell lung cancer (NSCLC) driven by the epidermal growth factor receptor (EGFR).
- It was found that A3B expression can limit tumor growth in mouse models but is linked to resistance against EGFR-targeted therapies in tumors.
- The research suggests that A3B could be targeted to improve the effectiveness of cancer treatments, as its upregulation was observed in both preclinical models and patients undergoing EGFR-targeted therapy.
Towards a balanced value business model for personalized medicine: an outlook.
Pharmacogenomics
January 2013
Novel targeted drugs, mainly in oncology, have commanded substantial price premiums in the recent past. Consequently, the attention of pharmaceutical companies has shifted away from the traditional low-price and high-volume blockbuster business model to drugs that command high, and sometimes extremely high, prices in limited markets defined by targeted patient populations. This model may have already passed its zenith, as the impact of more and more high-priced drugs coming to market substantially increases their combined burden on payors and public health finances.
View Article and Find Full Text PDF